Skip to main content
SpringerLink
Log in

Pharmacoeconomics of Systemic and Biologic Therapy in Dermatology

  • Chapter
  • First Online:
Biologic and Systemic Agents in Dermatology

Abstract

With rising costs of healthcare, economic cost analyses will continue to become important in the evaluation of pharmaceutical products and systemic therapies in dermatology. Understanding the basic principles of pharmacoeconomics and how they apply to dermatology is important for all dermatologists and medical trainees. In this chapter, we review the key concepts of pharmacoeconomics and give examples of these as they pertain to systemic therapy in psoriasis. Costs, including direct costs, indirect costs, opportunity costs, and intangible costs, are reviewed as are types of cost analyses and measurements of humanistic outcomes or clinical efficacy, such as utility scores, patient-reported outcomes, and number needed to treat. Finally, we present an example of a cost analysis for biologic agents in the treatment of psoriasis to emphasize the importance of pharmacoeconomic considerations in daily clinical practice for dermatologists.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  1. Statistics CNCfH. Health expenditures CDC. 2016. https://www.cdc.gov/nchs/fastats/health-expenditures.htm.

  2. Porter ME. What is value in health care? N Engl J Med. 2010;363(26):2477–81.

    Article  CAS  PubMed  Google Scholar 

  3. Trask LS. Chapter 1: Pharmacoeconomics: principles, methods, and applications. In: JT DP, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, editors. Pharmacotherapy: a pathophysiologic approach, 8e. New York, NY: McGraw-Hill; 2011.

    Google Scholar 

  4. Eisenberg JM. Clinical economics. A guide to the economic analysis of clinical practices. JAMA. 1989;262(20):2879–86.

    Article  CAS  PubMed  Google Scholar 

  5. Schmitt JM, Ford DE. Work limitations and productivity loss are associated with health-related quality of life but not with clinical severity in patients with psoriasis. Dermatology. 2006;213(2):102–10.

    Article  PubMed  Google Scholar 

  6. Hemp P. Presenteeism: at work—but out of it. Harv Bus Rev. 2004;82(10):49–58. 155

    PubMed  Google Scholar 

  7. Graham CN, McBride D, Miles L, Kneidl J, Mollon P. Estimation of indirect (work-related productivity) costs associated with moderate-to-severe plaque psoriasis in Germany. Value Health. 2015;18(7):A419.

    Article  CAS  PubMed  Google Scholar 

  8. Gencarelli DM. One pill, many prices: variation in prescription drug prices in selected government programs. Issue Brief George Wash Univ Natl Health Policy Forum. 2005;807:1–20.

    Google Scholar 

  9. Lewis V, Finlay AY. 10 years experience of the dermatology life quality index (DLQI). J Investig Dermatol Symp Proc. 2004;9(2):169–80.

    Article  PubMed  Google Scholar 

  10. Herédi E, Rencz F, Balogh O, Gulácsi L, Herszényi K, Holló P, et al. Exploring the relationship between EQ-5D, DLQI and PASI, and mapping EQ-5D utilities: a cross-sectional study in psoriasis from Hungary. Eur J Health Econ. 2014;15(Suppl 1):S111–9.

    Article  PubMed  Google Scholar 

  11. Walley T, Haycox A. Pharmacoeconomics: basic concepts and terminology. Br J Clin Pharmacol. 1997;43(4):343–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Riis PT, Vinding GR, Ring HC, Jemec GB. Disutility in patients with hidradenitis suppurativa: a cross-sectional study using EuroQoL-5D. Acta Derm Venereol. 2016;96(2):222–6.

    Article  PubMed  Google Scholar 

  13. Manriquez JJ, Villouta MF, Williams HC. Evidence-based dermatology: number needed to treat and its relation to other risk measures. J Am Acad Dermatol. 2007;56(4):664–71.

    Article  PubMed  Google Scholar 

  14. Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003;349(21):2014–22.

    Article  CAS  PubMed  Google Scholar 

  15. Gottlieb AB, Evans R, Li S, Dooley LT, Guzzo CA, Baker D, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2004;51(4):534–42.

    Article  PubMed  Google Scholar 

  16. Saurat JH, Stingl G, Dubertret L, Papp K, Langley RG, Ortonne JP, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol. 2008;158(3):558–66.

    Article  CAS  PubMed  Google Scholar 

  17. Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371(9625):1665–74.

    Article  CAS  PubMed  Google Scholar 

  18. Griffiths CE, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386(9993):541–51.

    Article  CAS  PubMed  Google Scholar 

  19. Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, et al. Secukinumab in plaque psoriasis--results of two phase 3 trials. N Engl J Med. 2014;371(4):326–38.

    Article  PubMed  Google Scholar 

  20. Briggs A, Sculpher M. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics. 1998;13(4):397–409.

    Article  CAS  PubMed  Google Scholar 

  21. Weinstein MC, Torrance G, McGuire A. QALYs: the basics. Value Health. 2009;12(Suppl 1):S5–9.

    Article  PubMed  Google Scholar 

  22. Whitehead SJ, Ali S. Health outcomes in economic evaluation: the QALY and utilities. Br Med Bull. 2010;96:5–21.

    Article  PubMed  Google Scholar 

  23. Jain R, Grabner M, Onukwugha E. Sensitivity analysis in cost-effectiveness studies: from guidelines to practice. Pharmacoeconomics. 2011;29(4):297–314.

    Article  PubMed  Google Scholar 

  24. Mease PJ, Menter MA. Quality-of-life issues in psoriasis and psoriatic arthritis: outcome measures and therapies from a dermatological perspective. J Am Acad Dermatol. 2006;54(4):685–704.

    Article  PubMed  Google Scholar 

  25. Gutknecht M, Krensel M, Augustin M. Health economic analyses of psoriasis management: a systematic literature search. Arch Dermatol Res. 2016;308(9):601–16.

    Article  PubMed  Google Scholar 

  26. Nelson AA, Pearce DJ, Fleischer AB, Balkrishnan R, Feldman SR. Cost-effectiveness of biologic treatments for psoriasis based on subjective and objective efficacy measures assessed over a 12-week treatment period. J Am Acad Dermatol. 2008;58(1):125–35.

    Article  PubMed  Google Scholar 

  27. D'Souza LS, Payette MJ. Estimated cost efficacy of systemic treatments that are approved by the US Food and Drug Administration for the treatment of moderate to severe psoriasis. J Am Acad Dermatol. 2015;72(4):589–98.

    Article  PubMed  Google Scholar 

  28. Armstrong AW, Betts KA, Sundaram M, Thomason D, Signorovitch JE. Comparative efficacy and incremental cost per responder of methotrexate versus apremilast for methotrexate-naïve patients with psoriasis. J Am Acad Dermatol. 2016;75(4):740–6.

    Article  CAS  PubMed  Google Scholar 

  29. (ICER) IfCaER. Targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: effectiveness and value. 2016. https://icer-review.org/wp-content/uploads/2016/12/NE_CEPAC_Psoriasis_Evidence_Report_FINAL_120216.pdf.

  30. Shahwan K, Kimball A. Managing the dose escalation of biologics in an era of cost containment: the need for a rational strategy. Int J Womens Dermatol. 2016;2(4):151–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, Clinical Laboratory for Epidemiology and Applied Research in Skin (CLEARS), Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA, 02215, USA

    Martina L. Porter MD

  2. Department of Dermatology, Harvard Medical School, Beth Israel Deaconess Medical Center, 375 Longwood Ave, Boston, MA, 02215, USA

    Alexa B. Kimball MD, MPH

Authors
  1. Martina L. Porter MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alexa B. Kimball MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alexa B. Kimball MD, MPH .

Editor information

Editors and Affiliations

  1. Division of Dermatology, David Geffen School of Medicine a UCLA, Los Angeles, California, USA

    Paul S. Yamauchi

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Porter, M.L., Kimball, A.B. (2018). Pharmacoeconomics of Systemic and Biologic Therapy in Dermatology. In: Yamauchi, P. (eds) Biologic and Systemic Agents in Dermatology. Springer, Cham. https://doi.org/10.1007/978-3-319-66884-0_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-66884-0_10

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-66883-3

  • Online ISBN: 978-3-319-66884-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation